Ignite Creation Date:
2024-05-06 @ 10:18 AM
Last Modification Date:
2024-10-26 @ 12:27 PM
Study NCT ID:
NCT03213665
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-05-21
First Post:
2017-07-10
Brief Title:
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors Non-Hodgkin Lymphoma or Histiocytic Disorders With EZH2 SMARCB1 or SMARCA4 Gene Mutations A Pediatric MATCH Treatment Trial
Sponsor:
National Cancer Institute NCI
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Wilms Tumor |
| Advanced Malignant Solid Neoplasm |
| Ann Arbor Stage III Hodgkin Lymphoma |
| Ann Arbor Stage III Non-Hodgkin Lymphoma |
| Ann Arbor Stage IV Hodgkin Lymphoma |
| Ann Arbor Stage IV Non-Hodgkin Lymphoma |
| Ewing SarcomaPeripheral Primitive Neuroectodermal Tumor |
| Low Grade Glioma |
| Recurrent Ependymoma |
| Recurrent Ewing Sarcoma |
| Recurrent Glioma |
| Recurrent Hepatoblastoma |
| Recurrent Hodgkin Lymphoma |
| Recurrent Langerhans Cell Histiocytosis |
| Recurrent Malignant Germ Cell Tumor |
| Recurrent Malignant Glioma |
| Recurrent Malignant Solid Neoplasm |
| Recurrent Medulloblastoma |
| Recurrent Neuroblastoma |
| Recurrent Non-Hodgkin Lymphoma |
| Recurrent Osteosarcoma |
| Recurrent Peripheral Primitive Neuroectodermal Tumor |
| Recurrent Primary Central Nervous System Neoplasm |
| Recurrent Rhabdoid Tumor |
| Recurrent Rhabdomyosarcoma |
| Recurrent Soft Tissue Sarcoma |
| Refractory Hodgkin Lymphoma |
| Refractory Langerhans Cell Histiocytosis |
| Refractory Malignant Germ Cell Tumor |
| Refractory Malignant Glioma |
| Refractory Malignant Solid Neoplasm |
| Refractory Medulloblastoma |
| Refractory Neuroblastoma |
| Refractory Non-Hodgkin Lymphoma |
| Refractory Osteosarcoma |
| Refractory Peripheral Primitive Neuroectodermal Tumor |
| Refractory Rhabdoid Tumor |
| Refractory Soft Tissue Sarcoma |
| Rhabdoid Tumor |
| Stage III Soft Tissue Sarcoma AJCC v7 |
| Stage IV Soft Tissue Sarcoma AJCC v7 |
Keywords: